Agenus Inc (AGEN) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 2[1], 1 Phase 1[2].
AGEN has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].
AGEN is tracked by BiotechSign with a current catalyst score of 69/100 and grade B. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Agenus Inc (AGEN) has a BiotechSign Catalyst Score of 69/100, rated B. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Agenus Inc (AGEN) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 2[1], 1 Phase 1[2].
AGEN has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].